{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:55:33Z","timestamp":1790963733726,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Neurelis, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40268-021-00360-5","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T16:02:47Z","timestamp":1629907367000},"page":"361-369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Improvement of Intranasal Drug Delivery with Intravail\u00ae Alkylsaccharide Excipient as a Mucosal Absorption Enhancer Aiding in the Treatment of Conditions of the Central Nervous System"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1299-0606","authenticated-orcid":false,"given":"Adrian L.","family":"Rabinowicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8788-0722","authenticated-orcid":false,"given":"Enrique","family":"Carrazana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-9963","authenticated-orcid":false,"given":"Edward T.","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"issue":"1","key":"360_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","volume":"3","author":"PG Djupesland","year":"2013","unstructured":"Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective: a review. Drug Deliv Transl Res. 2013;3(1):42\u201362.","journal-title":"Drug Deliv Transl Res"},{"issue":"9","key":"360_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/WOX.0b013e3181865f99","volume":"1","author":"LM Fromer","year":"2008","unstructured":"Fromer LM, Ortiz GR, Dowdee AM. Assessment of patient attitudes about mometasone furoate nasal spray: the ease-of-use patient survey. World Allergy Organ J. 2008;1(9):156\u20139.","journal-title":"World Allergy Organ J"},{"key":"360_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000321044","volume":"40","author":"C Bitter","year":"2011","unstructured":"Bitter C, Suter-Zimmermann K, Surber C. Nasal drug delivery in humans. Curr Probl Dermatol. 2011;40:20\u201335.","journal-title":"Curr Probl Dermatol"},{"issue":"1\u20132","key":"360_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.03.025","volume":"337","author":"HR Costantino","year":"2007","unstructured":"Costantino HR, et al. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm. 2007;337(1\u20132):1\u201324.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"360_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijpharm.2006.11.013","volume":"335","author":"AK Leonard","year":"2007","unstructured":"Leonard AK, et al. In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int J Pharm. 2007;335(1\u20132):138\u201346.","journal-title":"Int J Pharm"},{"issue":"2","key":"360_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/17425247.2020.1714589","volume":"17","author":"B Forbes","year":"2020","unstructured":"Forbes B, et al. A consensus research agenda for optimising nasal drug delivery. Expert Opin Drug Deliv. 2020;17(2):127\u201332.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"360_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0378-5173(00)00373-2","volume":"199","author":"L Li","year":"2000","unstructured":"Li L, et al. Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. Int J Pharm. 2000;199(1):65\u201376.","journal-title":"Int J Pharm"},{"issue":"1","key":"360_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13346-012-0111-1","volume":"3","author":"E Touitou","year":"2013","unstructured":"Touitou E, Illum L. Nasal drug delivery. Drug Deliv Transl Res. 2013;3(1):1\u20133.","journal-title":"Drug Deliv Transl Res"},{"issue":"7","key":"360_CR9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/jcph.1384","volume":"59","author":"P Krieter","year":"2019","unstructured":"Krieter P, et al. Enhanced intranasal absorption of naltrexone by dodecyl maltopyranoside: implications for the treatment of opioid overdose. J Clin Pharmacol. 2019;59(7):947\u201357.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"360_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.annemergmed.2017.02.015","volume":"70","author":"MA Rech","year":"2017","unstructured":"Rech MA, et al. When to pick the nose: out-of-hospital and emergency department intranasal administration of medications. Ann Emerg Med. 2017;70(2):203\u201311.","journal-title":"Ann Emerg Med"},{"issue":"4","key":"360_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1208\/s12248-015-9719-7","volume":"17","author":"ME Meredith","year":"2015","unstructured":"Meredith ME, Salameh TS, Banks WA. Intranasal delivery of proteins and peptides in the treatment of neurodegenerative diseases. AAPS J. 2015;17(4):780\u20137.","journal-title":"AAPS J"},{"key":"360_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jconrel.2014.06.053","volume":"189","author":"L Kozlovskaya","year":"2014","unstructured":"Kozlovskaya L, Abou-Kaoud M, Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route. J Control Release. 2014;189:133\u201340.","journal-title":"J Control Release"},{"issue":"6","key":"360_CR13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nn0602-849","volume":"5","author":"J Born","year":"2002","unstructured":"Born J, et al. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci. 2002;5(6):514\u20136.","journal-title":"Nat Neurosci"},{"issue":"3","key":"360_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/pharmaceutics11030113","volume":"11","author":"M Ghadiri","year":"2019","unstructured":"Ghadiri M, Young PM, Traini D. Strategies to enhance drug absorption via nasal and pulmonary routes. Pharmaceutics. 2019;11(3):113.","journal-title":"Pharmaceutics"},{"issue":"4","key":"360_CR15","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/epi.16847","volume":"62","author":"J Cloyd","year":"2021","unstructured":"Cloyd J, et al. Overcoming the challenges of developing an intranasal diazepam rescue therapy for the treatment of seizure clusters. Epilepsia. 2021;62(4):846\u201356.","journal-title":"Epilepsia"},{"key":"360_CR16","unstructured":"Maggio ET, Inventor; Aegis Therapeutics, LLC, assignee. Intranasal administration of active agents to the central nervous system. US patent US 8,883,728 B2, 2014."},{"issue":"6","key":"360_CR17","doi-asserted-by":"publisher","first-page":"566","DOI":"10.2174\/156720112803529828","volume":"9","author":"S Gizurarson","year":"2012","unstructured":"Gizurarson S. Anatomical and histological factors affecting intranasal drug and vaccine delivery. Curr Drug Deliv. 2012;9(6):566\u201382.","journal-title":"Curr Drug Deliv"},{"issue":"6","key":"360_CR18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.4155\/tde.14.41","volume":"5","author":"PG Djupesland","year":"2014","unstructured":"Djupesland PG, Messina JC, Mahmoud RA. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther Deliv. 2014;5(6):709\u201333.","journal-title":"Ther Deliv"},{"issue":"23","key":"360_CR19","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.3390\/molecules24234312","volume":"24","author":"FA Bruinsmann","year":"2019","unstructured":"Bruinsmann FA, et al. Nasal drug delivery of anticancer drugs for the treatment of glioblastoma: preclinical and clinical trials. Molecules. 2019;24(23):4312.","journal-title":"Molecules"},{"issue":"3","key":"360_CR20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.18433\/J3NC79","volume":"12","author":"A Pires","year":"2009","unstructured":"Pires A, et al. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci. 2009;12(3):288\u2013311.","journal-title":"J Pharm Pharm Sci"},{"issue":"7","key":"360_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/jps.2600760709","volume":"76","author":"C McMartin","year":"1987","unstructured":"McMartin C, et al. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci. 1987;76(7):535\u201340.","journal-title":"J Pharm Sci"},{"issue":"1\u20132","key":"360_CR22","first-page":"147","volume":"29","author":"Y Huang","year":"1998","unstructured":"Huang Y, Donovan MD. Large molecule and particulate uptake in the nasal cavity: the effect of size on nasal absorption. Adv Drug Deliv Rev. 1998;29(1\u20132):147\u201355.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"360_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s13346-012-0069-z","volume":"3","author":"ET Maggio","year":"2013","unstructured":"Maggio ET, Pillion DJ. High efficiency intranasal drug delivery using Intravail\u00ae alkylsaccharide absorption enhancers. Drug Deliv Transl Res. 2013;3(1):16\u201325.","journal-title":"Drug Deliv Transl Res"},{"issue":"2","key":"360_CR24","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/jps.21462","volume":"98","author":"SC Chen-Quay","year":"2009","unstructured":"Chen-Quay SC, et al. Identification of tight junction modulating lipids. J Pharm Sci. 2009;98(2):606\u201319.","journal-title":"J Pharm Sci"},{"issue":"12","key":"360_CR25","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1023\/A:1013330815253","volume":"18","author":"F Ahsan","year":"2001","unstructured":"Ahsan F, et al. Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats. Pharm Res. 2001;18(12):1742\u20136.","journal-title":"Pharm Res"},{"issue":"6","key":"360_CR26","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1210\/endo.135.6.7988421","volume":"135","author":"DJ Pillion","year":"1994","unstructured":"Pillion DJ, et al. Insulin delivery in nosedrops: new formulations containing alkylglycosides. Endocrinology. 1994;135(6):2386\u201391.","journal-title":"Endocrinology"},{"issue":"6","key":"360_CR27","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/jps.10150","volume":"91","author":"DJ Pillion","year":"2002","unstructured":"Pillion DJ, et al. Synthetic long-chain alkyl maltosides and alkyl sucrose esters as enhancers of nasal insulin absorption. J Pharm Sci. 2002;91(6):1456\u201362.","journal-title":"J Pharm Sci"},{"issue":"3","key":"360_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/epi.16449","volume":"61","author":"RE Hogan","year":"2020","unstructured":"Hogan RE, et al. Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers. Epilepsia. 2020;61(3):455\u201364.","journal-title":"Epilepsia"},{"issue":"5","key":"360_CR29","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/epi.16506","volume":"61","author":"RE Hogan","year":"2020","unstructured":"Hogan RE, et al. Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal\/peri-ictal) and nonseizure (interictal) conditions: a phase 1, open-label study. Epilepsia. 2020;61(5):935\u201343.","journal-title":"Epilepsia"},{"issue":"1","key":"360_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s10194-017-0740-3","volume":"18","author":"S Munjal","year":"2017","unstructured":"Munjal S, et al. A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine. J Headache Pain. 2017;18(1):31.","journal-title":"J Headache Pain"},{"issue":"9","key":"360_CR31","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/head.12905","volume":"56","author":"S Munjal","year":"2016","unstructured":"Munjal S, et al. A randomized trial comparing the pharmacokinetics, safety, and tolerability of DFN-02, an intranasal sumatriptan spray containing a permeation enhancer, with intranasal and subcutaneous sumatriptan in healthy adults. Headache. 2016;56(9):1455\u201365.","journal-title":"Headache"},{"issue":"2","key":"360_CR32","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/jps.20234","volume":"94","author":"PP Tirumalasetty","year":"2005","unstructured":"Tirumalasetty PP, Eley JG. Evaluation of dodecylmaltoside as a permeability enhancer for insulin using human carcinoma cells. J Pharm Sci. 2005;94(2):246\u201355.","journal-title":"J Pharm Sci"},{"issue":"4","key":"360_CR33","doi-asserted-by":"publisher","first-page":"a028241","DOI":"10.1101\/cshperspect.a028241","volume":"9","author":"XM Bustamante-Marin","year":"2017","unstructured":"Bustamante-Marin XM, Ostrowski LE. Cilia and mucociliary clearance. Cold Spring Harb Perspect Biol. 2017;9(4):a028241.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"360_CR34","first-page":"40","volume":"1","author":"ET Maggio","year":"2010","unstructured":"Maggio ET. Use of excipients to control aggregation in peptide and protein formulations. J Excip Food Chem. 2010;1(2):40\u20139.","journal-title":"J Excip Food Chem."},{"issue":"1","key":"360_CR35","first-page":"103","volume":"16","author":"N Mahjoubi","year":"2017","unstructured":"Mahjoubi N, et al. Effect of nonionic surfactants (dodecyl maltoside and polysorbate 20) on prevention of aggregation and conformational changes of recombinant human IFNbeta_1b induced by light. Iran J Pharm Res. 2017;16(1):103\u201311.","journal-title":"Iran J Pharm Res."},{"issue":"1","key":"360_CR36","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11481-010-9226-7","volume":"6","author":"RA Rifkin","year":"2011","unstructured":"Rifkin RA, et al. n-Dodecyl-beta-D-maltoside inhibits aggregation of human interferon-beta-1b and reduces its immunogenicity. J Neuroimmune Pharmacol. 2011;6(1):158\u201362.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"5","key":"360_CR37","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4155\/tde.13.19","volume":"4","author":"ET Maggio","year":"2013","unstructured":"Maggio ET. Alkylsaccharides: circumventing oxidative damage to biotherapeutics caused by polyoxyethylene-based surfactants. Ther Deliv. 2013;4(5):567\u201372.","journal-title":"Ther Deliv"},{"issue":"2","key":"360_CR38","first-page":"100","volume":"5","author":"ET Maggio","year":"2014","unstructured":"Maggio ET. Absorption enhancing excipients in systemic nasal drug delivery. J Excip Food Chem. 2014;5(2):100\u201312.","journal-title":"J Excip Food Chem."},{"issue":"12","key":"360_CR39","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1021\/acs.molpharmaceut.7b00297","volume":"14","author":"K Gradauer","year":"2017","unstructured":"Gradauer K, et al. Dodecylmaltoside modulates bicellular tight junction contacts to promote enhanced permeability. Mol Pharm. 2017;14(12):4734\u201340.","journal-title":"Mol Pharm"},{"issue":"1","key":"360_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0928-0987(03)00163-5","volume":"20","author":"F Ahsan","year":"2003","unstructured":"Ahsan F, et al. Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-beta-cyclodextrin, on insulin movement across human bronchial epithelial cells (16HBE14o-). Eur J Pharm Sci. 2003;20(1):27\u201334.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"360_CR41","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1002\/jps.21977","volume":"99","author":"JJ Arnold","year":"2010","unstructured":"Arnold JJ, et al. Reestablishment of the nasal permeability barrier to several peptides following exposure to the absorption enhancer tetradecyl-beta-d-maltoside. J Pharm Sci. 2010;99(4):1912\u201320.","journal-title":"J Pharm Sci"},{"issue":"4","key":"360_CR42","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/pharmaceutics10040172","volume":"10","author":"EM Danielsen","year":"2018","unstructured":"Danielsen EM, Hansen GH. Probing the action of permeation enhancers sodium cholate and N-dodecyl-\u03b2-D-maltoside in a porcine jejunal mucosal explant system. Pharmaceutics. 2018;10(4):172.","journal-title":"Pharmaceutics"},{"issue":"7","key":"360_CR43","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/jps.10171","volume":"91","author":"J Arnold","year":"2002","unstructured":"Arnold J, et al. Nasal administration of low molecular weight heparin. J Pharm Sci. 2002;91(7):1707\u201314.","journal-title":"J Pharm Sci"},{"issue":"3","key":"360_CR44","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/jps.10579","volume":"93","author":"F Mustafa","year":"2004","unstructured":"Mustafa F, et al. Chain length-dependent effects of alkylmaltosides on nasal absorption of enoxaparin. J Pharm Sci. 2004;93(3):675\u201383.","journal-title":"J Pharm Sci"},{"key":"360_CR45","unstructured":"Upsher-Smith Laboratories, LLC. Tosymra (sumatriptan). Full Prescribing Information. Maple Grove, MN: Upsher-Smith Laboratories, LLC; 2019."},{"issue":"5","key":"360_CR46","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/head.13309","volume":"58","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, et al. DFN-02 (sumatriptan 10 mg with a permeation enhancer) nasal spray vs placebo in the acute treatment of migraine: a double-blind, placebo-controlled study. Headache. 2018;58(5):676\u201387.","journal-title":"Headache"},{"key":"360_CR47","unstructured":"Wheless JW, et al. Safety of Valtoco (NRL-1; diazepam nasal spray) in patients with epilepsy: interim results from a phase 3, open-label, 12-month repeat dose study. Presented at: 73rd American Epilepsy Society Annual Meeting, December 6-10, 2019; Baltimore, MD."},{"key":"360_CR48","unstructured":"Neurelis, Inc. Valtoco (diazepam nasal spray). Full Prescribing Information. San Diego, CA: Neurelis, Inc.; 2021."},{"issue":"3","key":"360_CR49","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.eplepsyres.2013.02.018","volume":"105","author":"SK Agarwal","year":"2013","unstructured":"Agarwal SK, et al. A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. Epilepsy Res. 2013;105(3):362\u20137.","journal-title":"Epilepsy Res"},{"key":"360_CR50","doi-asserted-by":"crossref","unstructured":"Krieter P, et al. Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose. J Pharmacol Exp Ther. 2019;371(2):409\u201315.","DOI":"10.1124\/jpet.118.256115"}],"container-title":["Drugs in R&amp;D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-021-00360-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-021-00360-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-021-00360-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T18:22:48Z","timestamp":1675621368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-021-00360-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["360"],"URL":"https:\/\/doi.org\/10.1007\/s40268-021-00360-5","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"assertion":[{"value":"8 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Development of this manuscript was supported by Neurelis, Inc., which also sponsored open access.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Adrian L. Rabinowicz is an employee of and has received stock options from Neurelis, Inc. Enrique Carrazana is an employee of and has received stock and stock options from Neurelis, Inc. Edward T. Maggio is a consultant to Neurelis, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data sharing is not applicable to this article; no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"ETM provided initial interpretation of the studies. All authors provided additional interpretation, developed the initial outline, and contributed to the manuscript. All authors meet International Committee of Medical Journal Editors criteria for authorship. All authors approved the final version of this manuscript and agreed to submit to <i>Drugs in R&D.<\/i>","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}